Clinical trials: Pemetrexed
Adenocarcinoma of the Lung
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin or cisplatin) with pemetrexed…
- Trial name
- NCT01218516
- Testing
- Farletuzumab, Carboplatin, Paclitaxel
- Where
- 93 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Morphotek
Non Small Cell Lung Cancer
Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer
The purpose of this study is to look for an improvement in progression free survival with the combination of bevacizumab, carboplatin and pemetrexed in patients with newly diagnosed advanced/metastatic non small cell lung cancer.
- Trial name
- H3E-US-X072 (NCT00614822)
- Testing
- Carboplatin, Pemetrexed and Bevacizumab
- Volunteers
- 50 people
- Sponsor
- Christiana Care Health Services
Mesothelioma
Nintedanib (BIBF 1120) in Mesothelioma
This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin…
- Trial name
- NCT01907100
- Testing
- Nintedanib, Pemetrexed, Cisplatin
- Where
- 123 sites in United States, Argentina and 25 more
- Volunteers
- 545 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
This study will evaluate the efficacy and safety of chemotherapy given prior to having lung cancer surgically removed. Patients with resectable non-small cell lung cancer will receive gemcitabine and pemetrexed together for 4…
- Trial name
- NCT00226577
- Testing
- Gemcitabine, Pemetrexed, Surgery
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Head and Neck Cancer
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
The purpose of this study is to look at how well the combination of two chemotherapy drugs, pemetrexed (Alimta) and gemcitabine (Gemzar) work to treat your cancer.
- Trial name
- NCT00394147
- Testing
- pemetrexed, gemcitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Fox Chase Cancer Center
Nonsquamous Non-small Cell Lung Cancer
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
The purpose of this study is to assess the safety and efficacy of pemetrexed+platinum chemotherapy+pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults from mainland China with…
- Trial name
- NCT04716933
- Testing
- Pembrolizumab, Carboplatin, Cisplatin
- Where
- 19 sites in China
- Volunteers
- 201 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
This phase II trial studies how well Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in treating patients with stage I-IIIA non-small cell lung cancer that can be removed by surgery.
- Conditions
- Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
- Trial name
- NCT03366766
- Testing
- Nivolumab, Cisplatin, Pemetrexed Disodium
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Non-Small Cell Lung Cancer
A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer
This study will compare progression-free survival in patients with advanced non-squamous non-small cell lung cancer. Patients who do not progress following 4 cycles of induction treatment with pemetrexed and cisplatin will be…
- Trial name
- NCT00789373
- Testing
- Pemetrexed, Cisplatin, Best Supportive Care
- Where
- 68 sites in Australia, Belgium and 13 more
- Volunteers
- 939 people
- Sponsor
- Eli Lilly and Company
Pleural Mesothelioma, Malignant Pleural Mesothelioma
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
The purposes of this study are: to determine the feasibility of administering adjuvant cisplatin plus ALIMTA to patients who undergo surgery with heated cisplatin during surgery; to determine the effects (good and bad) of this…
- Trial name
- NCT00165503
- Testing
- Cisplatin, Sodium Thiosulfate, ALIMTA
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Non Small Cell Lung Cancer (NSCLC)
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
The purpose of this study was to determine if AUY922 had superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor had EGFR mutations.
- Trial name
- NCT01646125
- Testing
- AUY922, Docetaxel, Pemetrexed
- Where
- 27 sites in United States, France and 10 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasm, Malignant
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.
- Trial name
- NCT00732992
- Testing
- Sunitinib, Pemetrexed
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Neoplasms
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
This phase IB trial aims to identify anticancer activity of GSK3052230 in subjects with malignancies with abnormal dependence on FGF pathway signaling.
- Trial name
- NCT01868022
- Testing
- GSK3052230, paclitaxel, carboplatin
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 65 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combination of temsirolimus and pemetrexed, as well as the response rate.
- Trial name
- NCT00921310
- Testing
- Pemetrexed, Temsirolimus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Washington University School of Medicine
NSCLC Stage IIIB, NSCLC Stage IV
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive
- Trial name
- GFPC 06-2018 (NCT04042558)
- Testing
- Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab
- Where
- 31 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Francois Baclesse
Advanced Cancer
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
The purpose of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with standard doses of pemetrexed and cisplatin for the treatment of…
- Trial name
- NCT00106626
- Testing
- vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes need for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00520845
- Testing
- celecoxib, Docetaxel, pemetrexed disodium
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Cancer
Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as pemetrexed disodium and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the…
- Trial name
- NCT00268437
- Testing
- carboplatin, Pemetrexed, conventional surgery
- Where
- 90 sites in United States
- Volunteers
- 27 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
This is an open-label, non-randomized, Phase I study of epacadostat (INCB024360) alone and in combination with pembrolizumab with chemotherapy and pembrolizumab without chemotherapy in participants with advanced solid tumors.
- Trial name
- NCT02862457
- Testing
- Epacadostat 25 mg, Epacadostat 100 mg, pembrolizumab 200 mg
- Volunteers
- 34 people
- Sponsor
- Merck Sharp & Dohme LLC
NSCLC Stage IV, NSCLC, Recurrent
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
This is a multicenter single arm phase II clinical trial. All eligible patients will receive: Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v.
- Trial name
- NCT03713944
- Testing
- Carboplatin, Pemetrexed, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nasser Hanna
Non Small Cell Lung Cancer
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
The primary purpose of this study is to evaluate the efficacy and safety of LY2603618 in combination with pemetrexed and any side effects that might be associated with it along with determining the effects of LY2603618 in…
- Trial name
- NCT00988858
- Testing
- LY2603618, Pemetrexed
- Where
- 13 sites in United States, Italy and 2 more
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company